Navigation Links
Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Panmira Pharmaceuticals, LLC and FLAP, LLC, today announced their formation around certain assets spun out immediately preceding the acquisition of Amira Pharmaceuticals, Inc. (Amira) by Bristol-Myers Squibb Company (NYSE: BMY).  Panmira Pharmaceuticals received a number of assets, including Amira's DP2 antagonists, AM211 and AM461, both of which have successfully completed Phase I clinical studies.  FLAP, LLC is a non-operating company with rights to future milestones and royalties from Amira's 2008 licensing deal with GlaxoSmithKline related to the 5-lipoxygenase-activating protein (FLAP) inhibitor program.

"Now that we have successfully completed the sale of Amira to Bristol-Myers Squibb Company, a subset of the former Amira team will focus on completing our partnership efforts for the DP2 program," said Bob Baltera, Chief Executive Officer of Panmira Pharmaceuticals.  "We believe that spinning out these assets will be the best way to maximize their value for Amira's shareholders, and we look forward to accomplishing this goal."

Hari Kumar, Ph.D., Chief Business Officer, added, "Clinical trial results have demonstrated a dose proportional pharmacodynamic (PD) effect and good safety profiles for both AM211 and AM461.  These compounds are primed and ready for Phase II exploration in a number of clinical settings, including asthma, chronic obstructive pulmonary disease (COPD) and eosinophillic esophagitis.  We look forward to having the right partner to help make these plans come to fruition."

While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for the target to be a novel, potentially disease-modifying treatment of asthma, COPD and allergic rhinitis. DP2, also known as chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes (CRTH2), is a high affinity receptor for the prostaglandin D2 and is impli
'/>"/>

SOURCE Panmira Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
2. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
3. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
5. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
6. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
7. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
8. Visage Imaging Releases Amira 5.3
9. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
10. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
11. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SAN DIEGO , July 29, 2015 /PRNewswire/ ... Thursday, July 23, called the Alvarado Spine & ... orthopedic surgery and rehabilitation, focusing on spinal surgery ... method of patient care takes a patient experience-focused ... whatever clothing they feel comfortable in, rather than ...
(Date:7/29/2015)... , July 29, 2015  Cryoport, ... the "Company"), the leading provider of advanced ... industry, serving markets including immunotherapies, stem cells, ... animal health, and reproductive medicine, announced today ... of common stock and warrants (the "Units") under a ...
(Date:7/29/2015)... N.J. , July 29, 2015  Ortho-Clinical Diagnostics, ... five assays under development. The assays address a range ... kidney injury and cardiac troponin I. The scientific posters ... Clinical Chemistry Annual Meeting to be held July 26 ...   "Ortho Clinical Diagnostics is emerging stronger ...
Breaking Medicine Technology:The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3
... Mass., Oct. 22 Repligen Corporation (Nasdaq: RGEN ... for the second quarter of fiscal year 2011, on Tuesday, ... and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host ... 3:00 p.m. EDT, to discuss the financial results and provide ...
... Oct. 22 The American College of Emergency Physicians, ... is educating the public about safe disposal of expired, ... the threat of drug abuse by children.  Seventy percent ... got them from friends or relatives and a recent ...
Cached Medicine Technology:Repligen Announces Conference Call of Second Quarter Fiscal Year 2011 Results Tuesday, November 2nd, 3:00 p.m. EDT 2Repligen Announces Conference Call of Second Quarter Fiscal Year 2011 Results Tuesday, November 2nd, 3:00 p.m. EDT 3Emergency Physicians Urge Americans to Take The American Medicine Chest Challenge November 13th 2
(Date:7/29/2015)... ... July 29, 2015 , ... According to The Spirits Business ... is directly responsible for stimulating and perpetuating alcohol use disorders. Humans have the same ... of the National academy of Sciences, and has given researchers inklings to explore Rsu1 ...
(Date:7/29/2015)... ... 29, 2015 , ... According to the Miami Herald on July ... mental health disorders. Acu-detox may begin taking off in the South Florida community as ... addiction. Although acupuncture is not a new practice, it is not widely used, but ...
(Date:7/29/2015)... ... July 29, 2015 , ... San Fernando Valley skin doctor , Dr. ... time only, patients can get the complete treatment process with a 10 percent discount ... non-invasive treatment and have loose or sagging skin. , As the only non-surgical ...
(Date:7/29/2015)... ... 2015 , ... Today marks a significant achievement in bringing new monies into ... is led by a group of experienced investors, has tapped into an investor community ... to be a part of the fund. The Sofia Fund II is now ...
(Date:7/29/2015)... ... , ... CanAm Enterprises, LLC (“CanAm”) is thrilled to announce that more than ... been granted to investors in four different CanAm EB-5 projects -- the Sony and ... and the Valley Forge Convention Center project in CanAm’s regional center in partnership with ...
Breaking Medicine News(10 mins):Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3Health News:San Fernando Valley Dermatology Office, Castle Dermatology Institute, is Now Offering a Promotional Price on Ultherapy 2Health News:Sofia Fund Surpasses Investor Goals 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 2Health News:More Than 60 New I-829 Approvals in Less Than 30 days for CanAm 3
... happen to posses a certain gene mutation, your risks of ... question is a specific variation for hereditary hemochromatosis. This is ... affects how the body metabolizes iron, which results an iron ... condition causes liver enlargement that can lead to cirrhosis or ...
... reduced blood glucose levels in obese diabetic mice, ... a new study from Japan. ,"Dietary ... of hyperglycaemia in diabetic obese mice," wrote lead ... dietary intake of food or drinks produced from ...
... we are familiar with terms like ‘grumpy old man’, ‘old fogies’ ... Colorado University//. Surprisingly, it’s older people who are more optimistic about ... as they get older, and it is the young who tend ... , As part of a survey of 150 persons, the subjects ...
... chemicals that can keep arteries healthy and prevent heart ... least one orange// a day could keep cardiac disease ... that reduced blood cholesterol levels by 20-25 percent during ... Daily Mail. ,The researchers at the Hebrew ...
... stress better than those live single, says a study that ... perception is that single people have a carefree lifestyle. But ... makes it easier to cope with the stresses and strains ... ,Psychologist Dr Roxane Gervais monitored the stress levels of ...
... researchers at Weill Cornell Medical College could prove a potent ... compound, called SS31, is able to cross the blood-brain barrier ... tissue damage. ,"In our experiments, we found that ... to a much smaller area of brain tissue being affected," ...
Cached Medicine News:Health News:Gene Mutation Linked With Risks of Stroke 2Health News:Cocoa Polyphenols may Offer Diabetes Benefits - Study 2Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: